Method of making lyophilized microbubble compositions useful as contrast agents

• US 6,217,850 B1
• Filed: 05/26/1998
• Issued: 04/17/2001
• Est. Priority Date: 06/07/1995
• Status: Expired due to Term

• Current Assignee: GE Healthcare As (GE Healthcare Technologies, Inc.)
• Original Assignee: Nycomed Imaging AS (GE Healthcare Technologies, Inc.)
• Inventors: Dugstad, Harald, Rongved, Pål, Skurtveit, Roald, Klaveness, Jo, Braenden, Jorunn
• Primary Examiner(s): Hartley, Michael G.
• Application Number:
  US09/084,105
• Time in Patent Office: 1,057 Days
• Field of Search: 424/9.52, 424/9.51, 424/9.5, 424/450, 424/489, 600/441, 600/458, 428/402, 428/402.2, 516/10, 516/12, 516/77, 427/212, 427/213.3, 427/213.31
• US Class Current: 424/9.52
• CPC Class Codes: A61K 49/223 Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
• CPC Class Codes: A61K 49/227 Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
• CPC Class Codes: Y10T 428/2982 Particulate matter [e.g., sphere, flake, etc.]

Abstract

Microbubble dispersions stabilised by phospholipids predominantly comprising molecules which individually have an overall net charge exhibit advantageous stability, rendering them useful both as efficacious contrast agents per se and as intermediates in the preparation of contrast agents wherein the phospholipids are crosslinked or polymerised. An improved process for preparing microbubble-containing contrast agents is also disclosed, this comprising lyophilising an aqueous dispersion of gas microbubbles stabilised by one or more membrane-forming lipids to yield a dried product which may be reconstituted in an injectable carrier liquid to generate a microbubble-containing contrast agent.

Claims

1. A process for the preparation of a microbubble-releasing matrix comprising a cryoprotectant/lyoprotectant containing gas-filled substantially spherical cavities or vacuoles surrounded by layers of membrane-forming lipid material, wherein said gas is selected from the group consisting of sulphur hexafluoride, fluorinated low molecular weight hydrocarbons and mixtures of the foregoing, and wherein at least about 70% of said membrane-forming lipid material consists of one or more phosphatidylserines, said process comprising the steps:

i) dispersing said gas in an aqueous medium containing said membrane-forming lipid material to form a lipid-stabilised dispersion of microbubbles of said gas;

ii) adding said cryoprotectant/lyoprotectant to said dispersion; and

iii) lyophilising said dispersion to yield said microbubble-releasing matrix.

2. A process as claimed in claim 1 wherein said cryoprotectant/lyoprotectant is a carbohydrate.

3. A process as claimed in claim 2 wherein said carbohydrate is sucrose.

4. A process as claimed in claim 1 wherein said gas comprises a perfluorinated low molecular weight hydrocarbon.

5. A process as claimed in claim 4 wherein said perfluorinated low molecular weight hydrocarbon is selected from the group consisting of perfluoropropane, perfluorobutane and perfluoropentane.

6. A process as claimed in claim 1 wherein at least 80% of said membrane-forming lipid material consists of one or more phosphatidylserines.

7. A process as claimed in claim 1 wherein said phosphatidylserine or phosphatidylserines are selected from the group consisting of synthetic phosphatidylserine, semisynthetic phosphatidylserine, hydrogenated natural phosphatidylserine, hydrogenated semisynthetic phosphatidylserine, synthetic distearoylphosphatidylserine, synthetic dipalmitoylphosphatidylserine and synthetic diarachidoylphosphatidylserine.

8. A process as claimed in claim 1 wherein said gas is perfluorobutane and said phosphatidylserine is a dialkanoylphosphatidyl-serine.

9. A process as claimed in claim 1 wherein the aqueous medium employed in step (i) further contains one or more additives selected from the group consisting of viscosity enhancers and solubility aids for the lipid material.

10. A process as claimed in claim 9 wherein said additive or additives are selected from the group consisting of alcohols and polyols.

11. A process as claimed in claim 1 wherein the lipid-stabilised dispersion formed in step (i) is washed prior to steps (ii) and (iii).

12. A process as claimed in claim 1 wherein the lipid-stabilised dispersion formed in step (i) is size fractionated prior to steps (ii) and (iii).